A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity
NCT06693843 on ClinicalTrials.gov · last registry update 2026-08-10
An unusually large phase 2: 230 participants, more than double the 114 typical for the stage. The sponsor logged completion for 24 October 2025. Primary outcome, as filed: Percent change in body weight from Baseline to Week 36. aleniglipron is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended. The registry entry has been edited 1 time since then.
- Status
- COMPLETED
- Phase
- P2
- Drug
- aleniglipron
- Sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Sponsor type
- Industry
- Enrollment
- 230
- Started
- 2024-10-28
- Primary completion
- 2025-10-24 actual
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-08-21 | First seen in registry | Registered as COMPLETED, P2 |
Primary outcome
Percent change in body weight from Baseline to Week 36
Conditions studied
Obesity, Overweight, or Chronic Weight Management
Every field above is taken directly from the registry record. See all detected changes across the class, or the aleniglipron page for this molecule’s full trial and approval history.